Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Routine platelet transfusion in patients undergoing emergency coronary bypass surgery after receiving Abciximab AMERICAN JOURNAL OF CARDIOLOGY Juergens, C. P., Yeung, A. C., Oesterle, S. N. 1997; 80 (1): 74-?

Abstract

Abciximab has been shown to reduce the ischemic complications of high-risk angioplasty procedures. The appropriate management of patients who have received abciximab and require emergency coronary artery bypass surgery after failed coronary angioplasty is as yet undetermined. We present the outcomes of a small series of such patients who were given platelet transfusions before or during cardiopulmonary bypass.

View details for Web of Science ID A1997XG42400015

View details for PubMedID 9205024